Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies
- PMID: 8643884
- DOI: 10.1002/(SICI)1097-0258(19960215)15:3<263::AID-SIM165>3.0.CO;2-K
Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies
Abstract
In clinical research, randomized trials are widely accepted as the definitive method of evaluating the efficacy of therapies. Random assignment of patients to treatment ensures internal validity of the comparison of new treatments with controls. An assessment of external validity can best be achieved by comparing the randomized study sample to the population of patients who met the eligibility criteria but did not consent to randomization. The Comprehensive Cohort Study (CCS) is designed to recruit all patients fulfilling the clinical eligibility criteria regardless of their consent to randomization. The CCS concept was adopted in the major clinical trials of the German Breast Cancer Study Group (GBSG) conducted between 1983 and 1989. In this period 124 centres recruited 2084 patients in three clinical trials. 734 (35 per cent) of these patients accepted being randomized, while 1350 (65 per cent) chose one of the treatments under study; the randomization rates differed remarkably between trials. In this paper we examine the representativeness of the randomized patients in the three trials. Based on a median follow-up of about 5 years we present results on the external validity of the treatment effects estimated in the randomized patients by means of Cox's proportional hazards model and compare them between trials. We discuss advantages and disadvantages of the CCS design and conclude that its use is only justified under extraordinary circumstances.
Similar articles
-
Analysis of randomized and nonrandomized patients in clinical trials using the comprehensive cohort follow-up study design.Control Clin Trials. 1992 Jun;13(3):226-39. doi: 10.1016/0197-2456(92)90005-k. Control Clin Trials. 1992. PMID: 1320559 Clinical Trial.
-
[The Comprehensive Cohort Design as alternative to the randomized controlled trial in rehabilitation research: advantages, disadvantages, and implementation in the SARAH study].Rehabilitation (Stuttg). 2003 Dec;42(6):343-9. doi: 10.1055/s-2003-45457. Rehabilitation (Stuttg). 2003. PMID: 14677105 Clinical Trial. German.
-
Long-term follow-up of patients in four prospective studies of the German Breast Cancer Study Group (GBSG): A summary of key results.Onkologie. 2002 Apr;25(2):143-50. doi: 10.1159/000055224. Onkologie. 2002. PMID: 12006765
-
Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?Breast Cancer Res Treat. 2010 Jul;122(1):27-34. doi: 10.1007/s10549-010-0917-9. Epub 2010 May 8. Breast Cancer Res Treat. 2010. PMID: 20454925 Review.
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840 Review.
Cited by
-
A complex nursing intervention of complementary and alternative medicine (CAM) to increase quality of life in patients with breast and gynecologic cancer undergoing chemotherapy: study protocol for a partially randomized patient preference trial.Trials. 2015 Feb 15;16:51. doi: 10.1186/s13063-014-0538-4. Trials. 2015. PMID: 25887713 Free PMC article. Clinical Trial.
-
Primary care research after the Act: why commissioners and academia need to work together.Br J Gen Pract. 2012 May;62(598):232-3. doi: 10.3399/bjgp12X641285. Br J Gen Pract. 2012. PMID: 22546568 Free PMC article. No abstract available.
-
Power and Sample Size Calculations for the Restricted Mean Time Analysis of Prioritized Composite Endpoints.Stat Biopharm Res. 2023;15(3):540-548. doi: 10.1080/19466315.2022.2110936. Epub 2022 Oct 3. Stat Biopharm Res. 2023. PMID: 37663164 Free PMC article.
-
Systematic review to determine whether participation in a trial influences outcome.BMJ. 2005 May 21;330(7501):1175. doi: 10.1136/bmj.330.7501.1175. BMJ. 2005. PMID: 15905256 Free PMC article. Review.
-
Does enrollment in cancer trials improve survival?J Am Coll Surg. 2013 Apr;216(4):774-80; discussion 780-1. doi: 10.1016/j.jamcollsurg.2012.12.036. Epub 2013 Feb 13. J Am Coll Surg. 2013. PMID: 23415510 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical
Miscellaneous